The potential role of curcumin in patients with monoclonal gammopathy of undefined significance - Its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5917-5922

  Golombick, Terry ^a   Diamond, Terrence H ^a   Badmaev, Vladimir ^c   Manoharan, Arumugam ^b   Ramakrishna, Rajeev ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c SABINSA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BETA 2 MICROGLOBULIN; CALCIFEDIOL; CALCIUM; CURCUMIN; IMMUNOGLOBULIN; PARAPROTEIN; PLACEBO;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ELECTROPHORESIS; FEMALE; HUMAN; MALE; MONOCLONAL GAMMOPATHY OF UNDEFINED SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOCLAST; PARAPROTEINEMIA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINALYSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; CURCUMIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 70349466801     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2217     Document Type: Article

References (18)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Best Practice and Research Clinical Haematology 2005;18:689-707.
2. Melton LJ, Rajkumar V, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;19:25-30. (Pubitemid 41295134)
3. Bataille R, Chappard D, Basle M-F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996;87:4762-4769 (Pubitemid 26162377)
4. Woitge HW, Horn E, Keck AV, et al. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001;47:686-693 (Pubitemid 32275812)
5. Diamond T, Levy S, Smith A, et al. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 2001;31:272-278 (Pubitemid 32734930)
6. Cook L, Macdonald DHC. Management of paraproteinaemia. Postgrad Med J 2007;83:217-223
7. Aggarwal BB, Kumar A, Aggarwal MS, Shisodia S. Curcumin derived from turmeric Curcuma longa: a spice for all seasons. Phytopharmaceuticals in Cancer Chemoprevention 2005;349-387
8. Sharma RA, Euden SA, Platton SL, et al. Phase 1 Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance. Clin Cancer Res 2004;10:6847-6854
9. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10-14
10. κBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-1062
11. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-KB ligand-induced NF-KB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004;172:5940-5947 (Pubitemid 38621193)
12. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004;351:1860-1873
13. Vadhan-Raj S, Weber DM, Wang M, et al. Curcumin downregulates NF-KB and related genes in patients with multiple myeloma: results of a phase 1/11 study. Blood 2007;110:1177a.
14. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935 (Pubitemid 46223998)
15. Politou M, Terpos E, Angnostopoulos A, et al. Role of receptor activator of nuclear factor-κ B ligand (RANKL), osteoprotegerin and macrophage protein 1-α (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004;126:686-689 (Pubitemid 39221304)
16. Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997;90:3743-3750 (Pubitemid 27473447)
17. Jacob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-1 collagen (ICTP), amino-terminal collagen type-1 telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002;69:37-42. (Pubitemid 35155438)
18. Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion, and anti-metastatic effects of curcumin [review]. Adv Exp Med Biol 2007;595:173-184